Zhenyu Xu Sells 7,393 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Zhenyu Xu sold 7,393 shares of the firm’s stock in a transaction on Monday, July 6th. The shares were sold at an average price of $5.17, for a total value of $38,221.81. Following the completion of the sale, the insider owned 614,887 shares in the company, valued at $3,178,965.79. The trade was a 1.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Zhenyu Xu also recently made the following trade(s):

• On Monday, April 20th, Zhenyu Xu sold 608 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.21, for a total transaction of $3,167.68.
• On Tuesday, April 14th, Zhenyu Xu sold 600 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.97, for a total transaction of $2,982.00.
• On Monday, April 13th, Zhenyu Xu sold 4,414 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.76, for a total transaction of $21,010.64.
• On Friday, April 10th, Zhenyu Xu sold 3,706 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.68, for a total transaction of $17,344.08.
• On Thursday, April 9th, Zhenyu Xu sold 1,936 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.74, for a total transaction of $9,176.64.
• On Wednesday, April 8th, Zhenyu Xu sold 2,800 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.84, for a total transaction of $13,552.00.

SOPHiA GENETICS Price Performance

Shares of NASDAQ:SOPH opened at $5.51 on Thursday. The firm’s 50 day moving average is $5.15 and its two-hundred day moving average is $4.97. The firm has a market capitalization of $462.23 million, a P/E ratio of -10.60 and a beta of 0.96. The company has a current ratio of 2.06, a quick ratio of 1.90 and a debt-to-equity ratio of 1.05. SOPHiA GENETICS SA has a 52 week low of $2.92 and a 52 week high of $6.30.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). SOPHiA GENETICS had a negative return on equity of 62.74% and a negative net margin of 44.48%.The business had revenue of $21.69 million during the quarter, compared to the consensus estimate of $20.40 million.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in SOPH. Perkins Capital Management Inc. acquired a new stake in SOPHiA GENETICS in the fourth quarter worth approximately $49,000. Squarepoint Ops LLC acquired a new position in shares of SOPHiA GENETICS during the 3rd quarter valued at $49,000. First Dallas Securities Inc. acquired a new stake in shares of SOPHiA GENETICS in the first quarter valued at $50,000. Quadrature Capital Ltd acquired a new stake in shares of SOPHiA GENETICS in the fourth quarter valued at $54,000. Finally, XTX Topco Ltd acquired a new stake in shares of SOPHiA GENETICS in the fourth quarter valued at $55,000. Institutional investors and hedge funds own 31.59% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on SOPH shares. BTIG Research reissued a “buy” rating and issued a $8.00 price target on shares of SOPHiA GENETICS in a research note on Monday, June 15th. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Tuesday, April 21st. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $7.50.

Trending Headlines about SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: The insider sales were reported as pre-planned Rule 10b5-1 transactions tied to equity vesting and tax withholding, suggesting they may be administrative rather than a reflection of weakening business fundamentals.
• Neutral Sentiment: Several insiders sold shares in the same short period, including the chairman, CEO, CFO, and other executives, which keeps investor focus on insider activity. Article Title
• Negative Sentiment: A heavy run of insider selling can still pressure shares near term because some investors may interpret it as reduced confidence or increased stock supply.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.